Rtw Biotech Regulatory News (RTW)

LEI: 549300Q7EXQQH6KF7Z84

4 December 2025

RTW Biotech Opportunities Ltd

Inclusion in FTSE 250 Index

RTW Biotech Opportunities Ltd ("RTW Bio"), the London Stock Exchange-listed investment company focused on identifying transformative assets with high growth potential across the life sciences sector, is pleased to announce that its Ordinary Shares will be included in the FTSE 250 Index. This will be effective at the opening of trading today. This follows the inclusion of RTW Bio's shares in the FTSE All-Share Index from 22 September 2025.

Commenting on this development, William Simpson, Chair of RTW Bio, said:

"We are delighted that RTW Bio's Ordinary Shares will be included in the FTSE 250 Index from the opening of trading today. This constitutes another major milestone for RTW Bio and reflects the positive momentum delivered by the team to date, with the share price up 43% year-to-date and NAV performance ahead of key biotech indices and our peer group. We look forward to building upon this, with inclusion in the FTSE 250 Index likely to further enhance liquidity in our shares, deepen our investor base, and develop greater UK and international investor awareness of RTW Bio."

Enquiries:

About RTW Biotech Opportunities Ltd:

RTW Biotech Opportunities Ltd (LSE: RTW) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Biotech Opportunities Ltd invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives. RTW Biotech Opportunities Ltd is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

Visit the website at www.rtwfunds.com/rtw-biotech-opportunities-ltd for more information.

***********

The information in this announcement may include forward-looking statements, which are based on the current expectations and projections about future events, and in certain cases can be identified by the use of terms such as "may", "will", "should", "expect", "anticipate", "project", "estimate", "intend", "continue", "target", "believe" (or the negatives thereon) or other variations thereon or comparable terminology. These forward-looking statements, as well as those included in any related materials, are subject to risks, uncertainties and assumptions about the Company and/or its underlying investments, including, among other things, the development of the applicable entity's business, trends in its operating industry, expected use of financing proceeds and future capital expenditures and acquisitions. In light of these risks, uncertainties and assumptions, the events in the forward-looking statements may not occur.

The information contained in this announcement is given at the date of its publication (unless otherwise marked). No reliance may be placed for any purpose whatsoever on the information or opinions contained in this announcement or on its completeness, accuracy or fairness.

***********